Sustained Efficacy and Long-term Safety of Oxcarbazepine: One-year Open-label Extension of a Study in Refractory Partial Epilepsy
dc.contributor.author | Beydoun, Ahmad A. | en_US |
dc.contributor.author | Sachdeo, Rajesh C. | en_US |
dc.contributor.author | Kutluay, Ekrem | en_US |
dc.contributor.author | McCague, Kevin | en_US |
dc.contributor.author | D'Souza, Joseph | en_US |
dc.date.accessioned | 2010-04-01T15:11:22Z | |
dc.date.available | 2010-04-01T15:11:22Z | |
dc.date.issued | 2003-09 | en_US |
dc.identifier.citation | Beydoun, Ahmad; Sachdeo, Rajesh C.; Kutluay, Ekrem; McCague, Kevin; D'Souza, Joseph (2003). "Sustained Efficacy and Long-term Safety of Oxcarbazepine: One-year Open-label Extension of a Study in Refractory Partial Epilepsy." Epilepsia 44(9): 1160-1165. <http://hdl.handle.net/2027.42/65657> | en_US |
dc.identifier.issn | 0013-9580 | en_US |
dc.identifier.issn | 1528-1167 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/65657 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12919387&dopt=citation | en_US |
dc.description.abstract | Purpose: To evaluate the long-term efficacy, tolerability, and safety of oxcarbazepine (OXC) in medically refractory partial epilepsy. Methods: This study is the open-label extension phase that followed a multicenter, randomized, double-blind, dose-response clinical study of OXC monotherapy in patients with medically refractory partial epilepsy. We analyzed the efficacy, tolerability, and safety of OXC during the first 48 weeks of open-label therapy. To evaluate efficacy, we compared the change in seizure frequency throughout the 48 weeks of treatment with OXC with the baseline seizure frequency that preceded the double-blind phase of the core study by an intent-to-treat and completer analysis. Safety and tolerability were evaluated by using an intent-to-treat analysis. Results: Of the 87 patients enrolled in the double-blind study, 76 patients participated in the open-label extension phase. Fifty-five (72%) patients completed 48 weeks of open-label treatment on a median OXC dose of 2,400 mg/day. Based on an intent-to-treat analysis, the median reduction in seizure frequency was 47% (p = 0.0054) ; the 50 and 75% responder rates were 46.1 and 25.0%, respectively, with 6.6% of patients remaining seizure free. The completer analysis yielded comparable efficacy results. OXC was well tolerated, with 13% of patients exiting because of adverse events. The six most common adverse events, irrespective of their causal relation to OXC, were dizziness, headache, fatigue, diplopia, nausea, and rash. For the most part, these adverse events tended to be transient. Conclusions: The efficacy of OXC is sustained with good safety and tolerability profiles during long-term treatment of patients with medically refractory partial epilepsy. | en_US |
dc.format.extent | 82158 bytes | |
dc.format.extent | 3110 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | 2003 International League Against Epilepsy | en_US |
dc.subject.other | Oxcarbazepine | en_US |
dc.subject.other | Clinical Study | en_US |
dc.subject.other | Efficacy | en_US |
dc.subject.other | Adverse Events | en_US |
dc.subject.other | Epilepsy | en_US |
dc.title | Sustained Efficacy and Long-term Safety of Oxcarbazepine: One-year Open-label Extension of a Study in Refractory Partial Epilepsy | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | * Department of Neurology, University of Michigan Health System, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | † University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey | en_US |
dc.contributor.affiliationother | † Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, U.S.A. | en_US |
dc.identifier.pmid | 12919387 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/65657/1/j.1528-1157.2003.54102.x.pdf | |
dc.identifier.doi | 10.1046/j.1528-1157.2003.54102.x | en_US |
dc.identifier.source | Epilepsia | en_US |
dc.identifier.citedreference | McLean MJ. Oxcarbazepine: mechanisms of action. In : Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic drugs. 5th ed. Philadelphia : Lippincott Williams & Wilkins, 2001 : 451 – 8. | en_US |
dc.identifier.citedreference | Beydoun A, Kutluay E. Oxcarbazepine. Expert Opin Pharmacother 2002 ; 3 : 59 – 71. | en_US |
dc.identifier.citedreference | Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000 ; 54 : 2245 – 51. | en_US |
dc.identifier.citedreference | Sachdeo R, Beydoun A, Schachter SC, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001 ; 57 : 864 – 71. | en_US |
dc.identifier.citedreference | Sachdeo R, Edward K, Hasegawa H, et al. Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent onset partial epilepsy. Neurology 1999 ; 52 ( suppl 2 ): A391. | en_US |
dc.identifier.citedreference | Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999 ; 52 : 732 – 7. | en_US |
dc.identifier.citedreference | Glauser TA, Nigro M, Sachdeo RC, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000 ; 54 : 2237 – 44. | en_US |
dc.identifier.citedreference | Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine: placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000 ; 12 : 1597 – 607. | en_US |
dc.identifier.citedreference | Morrell MJ, McLean MJ, Willmore LJ, et al. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. Seizure 2000 ; 9 : 241 – 8. | en_US |
dc.identifier.citedreference | Bruni J. Outcome evaluation of gabapentin as add-on therapy for partial seizures: NEON Study Investigators Group: Neurontin evaluation of outcomes in neurological practice. Can J Neurol Sci 1998 ; 25 : 134 – 40. | en_US |
dc.identifier.citedreference | Abou-Khalil B and the Topiramate YOL Study Group. Topiramate in the long-term management of refractory epilepsy. Epilepsy 2000 ; 41 ( suppl 1 ): S72 – 6. | en_US |
dc.identifier.citedreference | Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence; the importance of rigorous methods. BMJ 1996 ; 313 : 36 – 9. | en_US |
dc.identifier.citedreference | Mazumdar S, Liu KS, Houck PR, et al. Intent-to-treat analysis for longitudinal clinical trials: coping with the challenge of missing values. J Psychiatr Res 1999 ; 33 : 37 – 95. | en_US |
dc.identifier.citedreference | Deckers CL. Place of polytherapy in the early treatment of epilepsy. CNS Drugs 2002 ; 16 : 155 – 6. | en_US |
dc.identifier.citedreference | Sachdeo RC, Wasserstein A, Mesenbrink PJ, et al. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol 2002 ; 51 : 613 – 20. | en_US |
dc.identifier.citedreference | Beydoun A. Monotherapy trials of new antiepileptic drugs. Epilepsia 1997 ; 38 : S21 – 31. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.